Emmyon is combining systems biology with medicinal chemistry to discover novel small molecules that safely and potently improve skeletal muscle function and whole-body metabolism. Our medicinal chemistry program is led by Dr. John Talley, who has been lead inventor of 8 FDA-approved drugs to date. Our work in this area is funded in part by the US National Institutes of Health. Beneficial effects of these molecules in pre-clinical models include treatment of skeletal muscle atrophy, induction of skeletal muscle hypertrophy, increased strength, reduced body fat and blood glucose, and prevention of obesity and pre-diabetes. Emmyon has granted and pending patents covering these novel molecules, which are being developed as pharmaceuticals for skeletal muscle atrophy, obesity and type 2 diabetes.